The DOI matches its Crossref record.
High expression of TROP2 correlates with poor prognosis in pancreatic cancer
Open accessAbstract
Pancreatic cancer is one of the most devastating human malignancies. Despite considerable research efforts, it remains resistant to almost all available treatment regimens. The human trophoblast cell-surface antigen, TROP2, was found to be strongly expressed in a variety of human epithelial cancers, correlating with aggressiveness and poor prognosis. TROP2 antigen expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series (n=197) of consecutive patients with pancreatic adenocarcinoma. Survival was calculated using Kaplan-Meier curves. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. TROP2 overexpression was observed in 109 (55%) of 197 pancreatic cancer patients and was significantly associated with decreased overall survival (P<0.01). By univariate analysis, TROP2 overexpression was found to correlate with the presence of lymph node metastasis (P=0.04) and tumour grade (P=0.01). Furthermore, in the subgroup of patients treated surgically with curative intent, TROP2 overexpression significantly correlated with poor progression-free survival (P<0.01). Multivariate analyses revealed TROP2 to be an independent prognosticator. These findings suggest for the first time that TROP2 could be a novel prognostic biomarker for pancreatic cancer. Targeting TROP2 might be a useful treatment approach for patients with pancreatic cancer overexpressing this cell-surface marker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Goldstein, A. S., Lawson, D. A., Cheng, D., Sun, W., Garraway, I. P., & Witte, O. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811411106 · Cited by 340
Komuta, M., Govaere, O., Vandecaveye, V., Akiba, J., Van Steenbergen, W., Verslype, C., Laleman, W., Pirenne, J., Aerts, R., Yano, H., et al. (2012) · Hepatology · doi:10.1002/hep.25595 · Cited by 333
Upregulation of Trop-2 quantitatively stimulates human cancer growth
Trerotola, M., Cantanelli, P., Guerra, E., Tripaldi, R., Aloisi, A. L., Bonasera, V, Lattanzio, R., Lange, R. D., Weidle, U. H., Piantelli, M., et al. (2013) · Oncogene · doi:10.1038/onc.2012.36 · Cited by 331
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Stepan, L. P., Trueblood, E. S., Hale, K., Babcook, J., Borges, L., & Sutherland, C. L. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410430 · Cited by 271
Trop2: A possible therapeutic target for late stage epithelial carcinomas
Cubas, R., Li, M., Chen, C., & Yao, Q. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.001 · Cited by 192
TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2
Zhao, P., & Zhang, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.7735 · Cited by 87
“Tumor-associated calcium signal transducer protein (TROP)-2 is a transmembrane glycoprotein expressed at high levels in a variety of human epithelial tumors, including oral (6), pancreatic (7), gastric (8), ovarian (9), lung (10), and prostate cancer (11).”
Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
Trerotola, M., Ganguly, K. K., Fazli, L., Fedele, C., Lu, H., Dutta, A., Liu, Q., De Angelis, T., Riddell, L. W., Riobo, N. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3960 · Cited by 70
ZHAO, P., YU, H.-Z., & CAI, J.-H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3900 · Cited by 24
Metadata
- Authors
- Fong, D., Moser, P., Krammel, C., Gostner, J. M., Margreiter, R., Mitterer, M., Gastl, G., & Spizzo, G.
- Venue
- British Journal of Cancer
- Published
- 2008-09-23
- Volume
- 99
- Issue
- 8
- Pages
- 1290-1295
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2045306661
- Cited by
- 237
- References
- 0
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.